These results suggest that FLT3 inhibitors given as pre-phase before chemotherapy does not impede the clinical response to salvage therapy in patients with relapsed/refractory FLT3-ITD-mutant AML while delivering rapid cytoreductions in those affected by severe hyperleukocytosis before chemotherapy. This evidence concerns the gene FLT3 and acute myeloid leukemia.